A potential new way to treat some of the most common blinding diseases

September 13, 2018, Elsevier
Vascular endothelial growth factor (VEGF)/tumor necrosis factor (TNF) induces retinal permeability and tight junction loss at the cell border. Rats were injected intravitreally with vehicle [0.1 percent bovine serum albumin (BSA) in phosphate-buffered saline (PBS)] or VEGF/TNF (50/10 ng). A: Fluorescent angiography using Micron III was performed at 5 hours after intravitreal cytokine injection, followed by intravenous injection of fluorescein isothiocyanate--conjugated (FITC) BSA (100 mg/kg body weight) and 10-minute circulation. Generally increased retinal fluorescence, with clear changes at the optic nerve head, is readily observed (Micron III). After angiography, retinas were dissected and flat mounted for microscopic visualization, where vascular leak from capillaries was readily observed (microscope). B: Flat-mount retinas were analyzed for immunoreactivity of occludin (Occ) and zonula occludens protein 1 (ZO-1). Loss of occludin and ZO-1 immunostaining at endothelial cell borders was observed in the VEGF/TNF-treated retinas. C: aPKC ζ inhibitor (aPKC ζ-I) blocks VEGF/TNF-induced permeability. Rats were intravitreally injected with vehicle (0.1 percent BSA in PBS), VEGF/TNF (50/10 ng), or indicated dose of aPKC ζ-I in combination with VEGF/TNF. At 3 hours after intravitreal injection, animals received an i.v. injection of FITC-BSA (100 mg/kg body weight). Two hours later, animals were perfused with warm saline and retinas were removed for quantification of FITC-BSA accumulation. Results are expressed relative to vehicle control. Differences between groups were analyzed by analysis of variance with Tukey's post hoc test. Data are expressed as means ± SEM (C). *P < 0.05, ****P < 0.0001. Original magnification, x630 (A, right column, and B). Credit: The American Journal of Pathology

Many eye diseases, including diabetic retinopathy and macular degeneration, exhibit increased permeability of blood vessels in the macular (central) portion of the retina leading to abnormal fluid accumulation and vision loss. Therapies targeting a specific cytokine, vascular endothelial growth factor (VEGF), have transformed clinical care; however, not all patients respond well. A new report in The American Journal of Pathology shows that inhibiting a specific signaling molecule, atypical protein kinase C (aPKC), either genetically or pharmacologically, reduces increased vessel permeability and blocks inflammation. Blocking aPKC may help protect vision in patients with potentially blinding eye diseases.

"Our data reveal aPKC as an interesting target both for vascular and inflammation and developing aPKC inhibitors may provide a new therapeutic option for blinding eye diseases," explained lead investigator David A. Antonetti, Ph.D., professor of Ophthalmology and Visual Sciences at The University of Michigan Kellogg Eye Center, Ann Arbor, MI, USA. "Our research may help patients with diabetic retinopathy, the leading cause of blindness in working age adults in the United States, and may also lead to new treatments for uveitis, a spectrum of diseases that leads to inflammation of the eye, as well as for retinal vein and artery occlusions."

Good vision requires retinal neurons to send signals to the brain, and retinal neurons must be protected and kept in a healthy microenvironment within the eye. This microenvironment is maintained, in part, by the selectively permeable blood-retinal-barrier (BRB). The BRB includes the tight junctions between the endothelial cells of the blood vessels that help control entry of water, nutrients, and ions to the retina. However, injury or chronic disease can weaken the BRB and increase vascular permeability by altering these endothelial tight junctions. Studies have shown that a variety of molecular factors can affect permeability, including growth factor VEGF and the inflammatory cytokine tumor necrosis factor alpha (TNFα). Although VEGF and TNFα possess distinct signaling mechanisms, both eventually activate a common pathway, aPKC signaling, to change the permeability of the endothelial cells of .

Further, aPKC promotes inflammation. In this study, investigators demonstrated the effects of VEGF and TNFα on retinal vascular permeability and the protective effect of an experimental small-molecule aPKC inhibitor using genetic mouse models and novel small molecule inhibitors to aPKC. The investigators also demonstrate the effect of targeting aPKC in a separate model of retinal inflammation. In both models, the genetic as well as therapeutic intervention reduced the vascular permeability and inflammation.

"This study evaluates the therapeutic potential of aPKC inhibition in retinal driven by inflammation and demonstrates that small molecule aPKC inhibitors have therapeutic potential for common ocular diseases," commented Elizabeth A. Pearsall, Ph.D., Angiogenesis Laboratory of the Department of Ophthalmology at the Massachusetts Eye and Ear Hospital of Harvard Medical School, Boston, MA, USA. in an accompanying commentary. She noted that although there are still many unresolved questions about the etiology of , and whether it has a causative role in , additional pre-clinical studies necessary to bring small molecule aPKC inhibitors into clinical use are eagerly anticipated.

The recent advent of drug delivery to the eye provides an exciting opportunity to protect vision. The importance of good vision combined with the ability to deliver a drug in a focused and contained environment in the eye have led to the prospects of increasing therapeutic options to help individuals suffering from vision loss.

Explore further: Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases

More information: "Inhibition of Atypical Protein Kinase C Reduces Inflammation-Induced Retinal Vascular Permeability," American Journal of Pathology (2018). DOI: 10.1016/j.ajpath.2018.06.020

Related Stories

Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases

July 27, 2012
Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because ...

Study suggests new way to prevent vision loss in diabetics and premature babies

March 22, 2017
Researchers at Bascom Palmer Eye Institute, part of the University of Miami Miller School of Medicine, have identified a new molecule that induces the formation of abnormal blood vessels in the eyes of diabetic mice. The ...

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

Loss of pericytes deteriorates retinal environment

May 16, 2017
Inside the eye, at the interface between blood vessels and the retina, lies a boundary that prevents harmful substances present in the blood from entering the retina. Researchers at the Center for Vascular Research, within ...

Protein responsible for 'bad' blood vessel growth discovered

July 17, 2013
The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels – the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis – ...

Recommended for you

Outbreak of preventable eye infection in contact lens wearers

September 21, 2018
A new outbreak of a rare but preventable eye infection that can cause blindness, has been identified in contact lens wearers in a new study led by UCL and Moorfields Eye Hospital researchers.

Newly formed blood vessels may contribute to eye disease

September 14, 2018
Newly formed blood vessels may be cracks in the barrier between the bloodstream and the eye, according to a Northwestern Medicine study published in the Proceedings of the National Academy of Sciences.

Eye disease can cause blindness, and it's on the rise

August 29, 2018
A new study into recent cases of ocular syphilis warns increasing numbers of people are at risk of permanent damage to their vision.

INSiGHT identifies unique retinal regulatory genes

August 28, 2018
Vision begins in the retina, a light-sensing neural network in the eye that is critical for our ability observe the world around us. Researches at Baylor College of Medicine, Texas Children's Hospital and the Hospital for ...

Alzheimer's one day may be predicted during eye exam

August 23, 2018
It may be possible in the future to screen patients for Alzheimer's disease using an eye exam.

Researchers find potential new gene therapy for blinding disease

August 20, 2018
The last year has seen milestones in the gene therapy field, with FDA approvals to treat cancer and an inherited blinding disorder. New findings from a team led by University of Pennsylvania vision scientists, who have in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.